What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-05-15 compared with 2022-11-03 · 34 added, 15 removed, 22 unchanged (69% of the section changed)

Other Information.

Number Description

3.1 Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).

3.2 Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).

3.3 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).

3.4 Amendment No.

1 to the Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 18 2022).

10.1 Amendment No.

1 to Securities Purchase Agreement, dated July 25, 2022, (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on July 26, 2022).

10.2 Form of Amendment No.1 to Common Stock Purchase Warrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on July 26, 2022).

Table of Content s

Number Description Filed Herewith Form Incorporated by Reference File No.

2.1△ Agreement and Plan of Merger, dated as of December 13, 2022, by and among Vallon Pharmaceuticals, Inc., GRI Bio, Inc., and Vallon Merger Sub, Inc.

8-K 001-40034 12/13/2022

2.2 Amendment to Agreement and Plan of Merger, dated as of February 17, 2023, by and among Vallon Pharmaceuticals, Inc., Vallon Merger Sub, Inc., and GRI Bio, Inc.

S-4/A 333-268977 2/24/2023

3.1 Certificate of Incorporation of GRI Bio, Inc., as amended.

8-K 001-40034 4/21/2023

3.2 Amended and Restated Bylaws.

8-K 001-40034 4/21/2023

4.1# A&R 2018 Equity Incentive Plan.

10.1 Form of Indemnification Agreement.

8-K 001-40034 4/21/2023

10.2# Employment Agreement, by and between GRI Bio, Inc.

and Marc Hertz, Ph.D., dated as of February 20, 2023.

S-4/A 333-268977 2/24/2023

10.3# Employment Agreement, by and between GRI Bio, Inc.

and Leanne M.

Kelly, dated as of February 20, 2023.

S-4/A 333-268977 2/24/2023

10.4# Employment Agreement, by and between GRI Bio, Inc.

and Vipin Kumar Chaturvedi dated as of February 20, 2023.

S-4/A 333-268977 2/24/2023

10.5# Consulting Agreement, by and between GRI Bio, Inc.

and Albert Agro, M.D., dated as of January 9, 2023.

8-K 001-40034 4/21/2023

31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

9 unchanged sentences

101.LAB iXBRL Taxonomy Extension Label Linkbase Document

Table of Content s

101.PRE iXBRL Taxonomy Extension Presentation Linkbase Document

2 unchanged sentences

Unless otherwise indicated, exhibits are filed herewith.

# Indicates a management contract or any compensatory plan, contract or arrangement.

△ Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S.

Securities and Exchange Commission.

* This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.

Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.

Table of Content s

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VALLON PHARMACEUTICALS, INC.

November 3, 2022 By:

GRI BIO, INC.

May 15, 2023 By:

/s/ Leanne M.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information